Supplement Table 1B.

Summary of Findings and Strength of Evidence (GRADE) for 30-Day Results

TAVI Compared to SAVR for Low-Risk Surgical Patients with Aortic Stenosis
Patient or population: Low-risk surgical patients with aortic stenosis Settings: Intervention: TAVI1 Comparison: SAVR2
Outcomes	Illustrative Comparative Risks* (95% CI)		Relative Effect (95% CI)	No. of Participants (Studies)	Quality of the Evidence (GRADE)	Comments
Assumed Risk	Corresponding Risk
	SAVR	TAVI
All-cause mortality Follow-up: 30 days	Study population		RR 0.44 (0.2-0.98)	2633 (3 studies)	⊕⊕⊕⊕ High
	15 per 1000	7 per 1000 (3-15)
	Moderate
13 per 1000	6 per 1000 (3-13)
Cardiovascular mortality Follow-up: 30 days	Study population		RR 0.47 (0.21-1.03)	2633 (3 studies)	⊕⊕⊕⊕ High
	14 per 1000	7 per 1000 (3-15)
	Moderate
13 per 1000	6 per 1000 (3-13)
Stroke Follow-up: 30 days	Study population		RR 0.57 (0.22-1.48)	2633 (3 studies)	⊕⊕⊕⊝ Moderate3
	30 per 1000	17 per 1000 (7-44)
	Moderate
30 per 1000	17 per 1000 (7-44)
Transient ischemic attack Follow-up: 30 days	Study population		RR 0.75 (0.17-3.37)	2633 (3 studies)	⊕⊕⊕⊕ High
	6 per 1000	5 per 1000 (1-21)
	Moderate
7 per 1000	5 per 1000 (1-24)
Myocardial infarction Follow-up: 30 days	Study population		RR 0.65 (0.34-1.22)	2633 (3 studies)	⊕⊕⊕⊕ High
	18 per 1000	12 per 1000 (6-22)
	Moderate
13 per 1000	8 per 1000 (4-16)
Acute kidney injury (stage 2 or 3) Follow-up: 30 days	Study population		RR 0.27 (0.14-0.56)	2633 (3 studies)	⊕⊕⊕⊕ High
	28 per 1000	8 per 1000 (4-16)
	Moderate
28 per 1000	8 per 1000 (4-16)
Life-threatening or disabling bleeding Follow-up: 30 days	Study population		RR 0.29 (0.14-0.61)	2633 (3 studies)	⊕⊕⊕⊝ Moderate3
	150 per 1000	43 per 1000 (21-91)
	Moderate
207 per 1000	60 per 1000 (29-126)
Permanent pacemaker implantation Follow-up: 30 days	Study population		RR 3.59 (1.43-9.03)	2633 (3 studies)	⊕⊕⊕⊕ High
	48 per 1000	173 per 1000 (69-435)
	Moderate
40 per 1000	144 per 1000 (57-361)
New-atrial fibrillation Follow-up: 30 days	Study population		RR 0.21 (0.14-0.31)	2633 (3 studies)	⊕⊕⊕⊕ High3,4
	365 per 1000	77 per 1000 (51-113)
	Moderate
354 per 1000	74 per 1000 (50-110)
*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). RR, risk ratio.
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.
1Transcatheter aortic valve implantation; 2surgical aortic valve replacement; 3inconsistency;4large effect.